173 related articles for article (PubMed ID: 17111253)
41. Mammographic density, response to hormones, and breast cancer risk.
Boyd NF; Melnichouk O; Martin LJ; Hislop G; Chiarelli AM; Yaffe MJ; Minkin S
J Clin Oncol; 2011 Aug; 29(22):2985-92. PubMed ID: 21709206
[TBL] [Abstract][Full Text] [Related]
42. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
Windler E; Zyriax BC; Eidenmüller B; Boeing H
Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571
[TBL] [Abstract][Full Text] [Related]
43. Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study.
Kelemen LE; Pankratz VS; Sellers TA; Brandt KR; Wang A; Janney C; Fredericksen ZS; Cerhan JR; Vachon CM
Am J Epidemiol; 2008 May; 167(9):1027-36. PubMed ID: 18385204
[TBL] [Abstract][Full Text] [Related]
44. Different types of postmenopausal hormone therapy and mammographic density in Norwegian women.
Bremnes Y; Ursin G; Bjurstam N; Lund E; Gram IT
Int J Cancer; 2007 Feb; 120(4):880-4. PubMed ID: 17131324
[TBL] [Abstract][Full Text] [Related]
45. Tumour size at detection according to different measures of mammographic breast density.
Nickson C; Kavanagh AM
J Med Screen; 2009; 16(3):140-6. PubMed ID: 19805755
[TBL] [Abstract][Full Text] [Related]
46. [Breast density: a major parameter to follow during hormone replacement therapy].
Gairard B; Guldenfels C; Haehnel P; Mathelin C
Gynecol Obstet Fertil; 2009; 37(7-8):657-60. PubMed ID: 19577502
[TBL] [Abstract][Full Text] [Related]
47. Mammographic density and estrogen receptor status of breast cancer.
Ziv E; Tice J; Smith-Bindman R; Shepherd J; Cummings S; Kerlikowske K
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2090-5. PubMed ID: 15598766
[TBL] [Abstract][Full Text] [Related]
48. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography.
Laya MB; Larson EB; Taplin SH; White E
J Natl Cancer Inst; 1996 May; 88(10):643-9. PubMed ID: 8627640
[TBL] [Abstract][Full Text] [Related]
49. Case-control study of increased mammographic breast density response to hormone replacement therapy.
Vachon CM; Sellers TA; Vierkant RA; Wu FF; Brandt KR
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1382-8. PubMed ID: 12433715
[TBL] [Abstract][Full Text] [Related]
50. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico.
Rosenberg RD; Hunt WC; Williamson MR; Gilliland FD; Wiest PW; Kelsey CA; Key CR; Linver MN
Radiology; 1998 Nov; 209(2):511-8. PubMed ID: 9807581
[TBL] [Abstract][Full Text] [Related]
51. Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence.
Buist DS; Walker R; Bowles EJ; Carney PA; Taplin SH; Onega T; Kerlikowske K; Clinton W; Miglioretti DL
Cancer Epidemiol Biomarkers Prev; 2012 May; 21(5):720-7. PubMed ID: 22301831
[TBL] [Abstract][Full Text] [Related]
52. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy.
Kerlikowske K; Zhu W; Hubbard RA; Geller B; Dittus K; Braithwaite D; Wernli KJ; Miglioretti DL; O'Meara ES;
JAMA Intern Med; 2013 May; 173(9):807-16. PubMed ID: 23552817
[TBL] [Abstract][Full Text] [Related]
53. Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users.
Ellingjord-Dale M; Lee E; Couto E; Ozhand A; Qureshi S; Hofvind S; Van Den Berg DJ; Akslen LA; Grotmol T; Ursin G
Breast Cancer Res; 2012 Oct; 14(5):R135. PubMed ID: 23095343
[TBL] [Abstract][Full Text] [Related]
54. Mammographic breast density and breast cancer risk: interactions of percent density, absolute dense, and non-dense areas with breast cancer risk factors.
Yaghjyan L; Colditz GA; Rosner B; Tamimi RM
Breast Cancer Res Treat; 2015 Feb; 150(1):181-9. PubMed ID: 25677739
[TBL] [Abstract][Full Text] [Related]
55. High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study.
Sala E; Warren R; McCann J; Duffy S; Luben R; Day N
Int J Epidemiol; 2000 Aug; 29(4):629-36. PubMed ID: 10922338
[TBL] [Abstract][Full Text] [Related]
56. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens.
Hofvind S; Møller B; Thoresen S; Ursin G
Int J Cancer; 2006 Jun; 118(12):3112-7. PubMed ID: 16395702
[TBL] [Abstract][Full Text] [Related]
57. Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland.
Koskela-Niska V; Riska A; Lyytinen H; Pukkala E; Ylikorkala O
Gynecol Oncol; 2012 Aug; 126(2):241-4. PubMed ID: 22561401
[TBL] [Abstract][Full Text] [Related]
58. Association between air pollution and mammographic breast density in the Breast Cancer Surveilance Consortium.
Yaghjyan L; Arao R; Brokamp C; O'Meara ES; Sprague BL; Ghita G; Ryan P
Breast Cancer Res; 2017 Apr; 19(1):36. PubMed ID: 28381271
[TBL] [Abstract][Full Text] [Related]
59. Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women?
Dieli-Conwright CM; Sullivan-Halley J; Patel A; Press M; Malone K; Ursin G; Burkman R; Strom B; Simon M; Weiss L; Marchbanks P; Folger S; Spirtas R; Deapen D; Bernstein L
Cancer Causes Control; 2011 Mar; 22(3):515-22. PubMed ID: 21213036
[TBL] [Abstract][Full Text] [Related]
60. The relationship of mammographic density and age: implications for breast cancer screening.
Checka CM; Chun JE; Schnabel FR; Lee J; Toth H
AJR Am J Roentgenol; 2012 Mar; 198(3):W292-5. PubMed ID: 22358028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
